CTOs on the Move

Techne Corporation

www.techne-corp.com

 
Techne Corporation , incorporated in Minnesota in 1981, is a holding company which has two wholly-owned operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) located in Minneapolis, Minnesota and R&D Systems Europe Ltd. (RDSE) located in Abingdon, England. Over 95% of TECHNE's revenues are derived from products developed and manufactured in-house. R&D Systems is a specialty manufacturer of biological products. It has two operating divisions: Hematology and Biotechnology. The Hematology Division develops and manufactures hematology controls, which are used in hospitals and clinical laboratories to check the accuracy of blood analysis instruments. The Biotechnology Division develops and manufactures biotechnology products ...
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

AccessDx Laboratory

Learn why 2,000+ healthcare organizations and employers depend on our experts to improve patient outcomes with advanced diagnostics.

IntegenX

IntegenX is a Pleasanton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hound Labs

Hound Labs combines science and technology in novel ways to improve health and wellness. The Company believes its ultra-sensitive and portable technologies will pave the way to practical and fair solutions for some of the leading public health and safety issues. In the coming month, Hound Labs will launch the HOUND® CANNABIS BREATHALYZER, which allows employers and law enforcement to identify recent cannabis in breath. Dr. Mike Lynn, an ER physician, reserve deputy sheriff, and former venture capitalist, founded Hound Labs in 2014.

Bayhill Therapeutics

Bayhill Therapeutics is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aligos Therapeutics

Aligos Therapeutics is discovering and developing new classes of compounds that interact directly with disease causing molecules. These approaches are targeting viral nucleic acids and their encoded proteins, as well as oncogenes and their resultant proteins. The company is also pursuing novel therapeutic agents aimed at activation of the immune system to resolve diseases that cause significant morbidity and mortality.